EFNA4: A Potential Drug Target and Biomarker (G1945)

Target Name: EFNA4

NCBI ID: G1945

EFNA4

EFNA4: A Potential Drug Target and Biomarker

The identification of potential drug targets and biomarkers is a crucial aspect of drug development. These targets and biomarkers can provide valuable information about the underlying disease and the response to therapeutic interventions. One such target that has gained significant attention in recent years is EFNA4.

EFNA4 is a gene that encodes a protein known as E-cadherin (E-CDH), which is a transmembrane protein that plays a critical role in cell-cell adhesion. EFNA4 has been identified as a potential drug target due to its involvement in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The E-cdherin gene has four splice variants, each of which has been associated with a distinct function in cell signaling. The most abundant splice variant is the E-cadherin splice variant I (EFNA4), which is a 21-kDa protein that is expressed in various tissues and organs, including brain, heart, liver, and pancreas.

EFNA4 functions as a negative regulator of the Wnt signaling pathway, which is a critical pathway involved in cell proliferation and differentiation. The Wnt signaling pathway plays a crucial role in the development and maintenance of tissues and organs, including brain and neural cells. However, when the Wnt signaling pathway is activated too frequently or for too long, it can lead to the formation of cancerous tumors.

EFNA4 is known to regulate the activity of the Wnt signaling pathway by blocking the activity of the transcription factor SMAD, which is a key player in the pathway. By blocking the activity of SMAD, EFNA4 promotes the production of pro-inflammatory cytokines, which have been linked to the development of various diseases, including cancer.

In addition to its role in cell signaling, EFNA4 has also been identified as a potential biomarker for several diseases. For example, high levels of E-cadherin have been associated with the development of various types of cancer, including breast, ovarian, and prostate cancer. Similarly, E-cadherin has also been linked to the development of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

The potential drug target for EFNA4 is based on its involvement in various diseases and its ability to regulate the Wnt signaling pathway. Drugs that target EFNA4 have the potential to treat diseases associated with the over-activation of the Wnt signaling pathway, including cancer, neurodegenerative diseases, and autoimmune disorders.

In conclusion, EFNA4 is a gene that has the potential to be a drug target for the treatment of various diseases. Its involvement in cell signaling and its association with the development of various diseases make it an attractive target for therapeutic intervention. Further research is needed to fully understand the role of EFNA4 as a drug target and its potential as a biomarker for disease.

Protein Name: Ephrin A4

Functions: Cell surface GPI-bound ligand for Eph receptors, a family of receptor tyrosine kinases which are crucial for migration, repulsion and adhesion during neuronal, vascular and epithelial development. Binds promiscuously Eph receptors residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. May play a role in the interaction between activated B-lymphocytes and dendritic cells in tonsils

The "EFNA4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EFNA4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets